retatrutide cognitive effects Half Life: A Doctor Explains in Simple Terms Substack Series 3 of 6:

Description

Study Selection The search results obtained from the 5 databases were imported into Endnote version 20 to eliminate any duplicate entries

Cardiometabolic benefits: At 48 weeks, improvements included triglyceride reductions up to 40.6% and apoC-III reductions of 38%, along with substantial weight loss (24%) Post-hoc analysis uncovered reductions in albuminuria (3037%) and increased eGFR (8.5 mL/min/1.73 m), suggesting potential kidney-protective effects TRIUMPH-3 and TRIUMPH-OUTCOMES are ongoing Phase 3 studies targeting Cardiovascular safety and outcomes and Renal function in obese individuals with ASCVD or CKD Future with Other GLP-1 and GIP Analogues (Poly-agonists) The development of multi-receptor agonists like retatrutide is the next-generation leap beyond GLP-1 monotherapy, holding potential efficacy comparable to bariatric surgery with fewer GI limitations

Ships from Ontario, Canada.

In a Chinese T2DM cohort treated with GLP-1R agonists, carriers of the GLP1R rs3765467 GG genotype experienced significantly greater HbA1c reduction compared to AA/AG genotypes [87]